KCT0009199招募中未知
Treatment of CD19 Chimeric Antigen Receptor T cells for Pediatric Patients with CD19-positive B-cell Acute Lymphoblastic Leukemia who are Indicated for Hematopoietic Stem Cell Transplantation
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- o Limit 至 25(Year)（—）
- 性别
- All
入选标准
- •* Subject eligibility criteria include individuals who are under the age of 25 at the time of SNUH-CD19-CAR-T administration. Confirmation of B-cell acute lymphoblastic leukemia diagnosed at the initial assessment by a treating physician for the first diagnosis is required. Immunophenotypic analysis of CD19 expression on leukemia cells must be confirmed through immune profiling at the time of the initial diagnosis of B-cell acute lymphoblastic leukemia. In patients experiencing hematologic relapse of B-cell acute lymphoblastic leukemia, CD19 expression should also be confirmed at the time of relapse confirmation.
- •Patients must achieve hematologic complete remission defined as less than 5% blasts in the bone marrow after the first-line or second-line chemotherapy (first salvage therapy). Eligible patients for hematopoietic stem cell transplantation, defined by indications for transplantation, include those meeting at least one of the following criteria:
- •a. Philadelphia chromosome-positive due to t(9;22)(q34;q11) translocation.
- •b. Hypodiploidy defined by fewer than 44 chromosomes.
- •c. E2A-HLF gene fusion due to t(17;19) translocation.
- •d. Detection of minimal residual disease (MRD) positive at 0.01% or higher by next-generation sequencing confirmed after consolidation therapy and maintenance therapy.
- •e. Failure of the first-line therapy.
- •f. Cases not meeting any of the above criteria but deemed eligible for hematopoietic stem cell transplantation based on the investigator's judgment.
排除标准
- •Patients who have undergone hematopoietic stem cell transplantation.
- •Individuals for whom an adequate or sufficient leukapheresis product suitable for the production of SNUH-CD19-CAR-T cannot be obtained or is unavailable.
- •Those known to be infected with the human immunodeficiency virus (HIV).
- •Presence of uncontrolled active infections, determined by the investigator's assessment. If appropriate treatment has been administered for the infection, and there are no signs of progression at the time of enrollment, it is considered controlled. Persistent fever without other symptoms is not interpreted as progressive infection.
- •Women who are pregnant or breastfeeding.
- •Individuals deemed clinically inappropriate for participation in the clinical trial based on the investigator's clinical judgment.
研究者
相似试验
进行中（未招募）
1 期
Immunotherapy with CD19? chimeric antigen receptor gene-modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia - CD19-CAR Immunotherapy for Childhood AEUCTR2007-007612-29-GBniversity College London29
进行中（未招募）
不适用
Immunotherapy with CD19? chimeric antigen receptor gene-modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia - CD19-CAR Immunotherapy for Childhood AThe medical condition under investigation is childhood precursor B acute lymphoblastic leukaemia (ALL).MedDRA version: 14.0Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-007612-29-DEniversity College London30
进行中（未招募）
1 期
Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia. Phase I/II clinical trial (MERMAID1)EUCTR2021-003409-23-PLMedical University of Warsaw20
Unknown
1 期
CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell MalignancyLymphomaLeukemiaNCT02537977Shanghai Tongji Hospital, Tongji University School of Medicine60
招募中
早期 1 期
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune NephritisImmune NephritisAutoimmune DiseasesLupus NephritisNCT05085418Zhejiang University9